Bone-targeted therapies to reduce skeletal morbidity in prostate cancer

Bone-targeted therapies to reduce skeletal morbidity in prostate cancer

Bone metastases are the main driver of morbidity and mortality in advanced prostate cancer. Targeting the bone microenvironment, a key player in the pathogenesis of bone metastasis, has become one of the mainstays of therapy in men with advanced prostate cancer. This review will evaluate the data su...

Full description

Bibliographic Details
Main Authors: Tanya B Dorff, Neeraj Agarwal
Format: Article
Language:English
Published: Wolters Kluwer Medknow Publications 2018-01-01
Series:Asian Journal of Andrology
Subjects:
bisphosphonate; bone metastases; prostate cancer; radiopharmaceutical; receptor activator of nuclear factor-kappa B-ligand
Online Access:http://www.ajandrology.com/article.asp?issn=1008-682X;year=2018;volume=20;issue=3;spage=215;epage=220;aulast=Dorff

Internet

http://www.ajandrology.com/article.asp?issn=1008-682X;year=2018;volume=20;issue=3;spage=215;epage=220;aulast=Dorff

Similar Items